A Multi-Center, Open-Label, Dose-Escalation Study to Evaluate the Safety, Efficacy, and Exposure to TRM-1 (Fully Human Monoclonal Antibody to the TRAIL-R1) in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma
Primary
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
GSK Clinical Trials
Study Director
GlaxoSmithKline
United States: Food and Drug Administration
TRM1-HM01
NCT00094848
June 2004
May 2007
Name | Location |
---|---|
MD Anderson Cancer Center | Houston, Texas 77030-4096 |
Roswell Park Cancer Institute | Buffalo, New York 14263 |
Mayo Clinic | Rochester, Minnesota 55905 |
Fox Chase Cancer Center | Philadelphia, Pennsylvania 19111 |
University of Nebraska Medical Center | Omaha, Nebraska 68198-3330 |
Memorial Sloan Kettering | New York, New York 10021 |
Sarah Cannon Research Institute | Nashville, Tennessee 37203 |